These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Diffuse Midline Gliomas with Histone H3-K27M Mutation: A Series of 47 Cases Assessing the Spectrum of Morphologic Variation and Associated Genetic Alterations. Solomon DA; Wood MD; Tihan T; Bollen AW; Gupta N; Phillips JJ; Perry A Brain Pathol; 2016 Sep; 26(5):569-80. PubMed ID: 26517431 [TBL] [Abstract][Full Text] [Related]
23. Inhibition of microglial EZH2 leads to anti-tumoral effects in pediatric diffuse midline gliomas. Keane L; Cheray M; Saidi D; Kirby C; Friess L; Gonzalez-Rodriguez P; Gerdes ME; Grabert K; McColl BW; Joseph B Neurooncol Adv; 2021; 3(1):vdab096. PubMed ID: 34485907 [TBL] [Abstract][Full Text] [Related]
24. Pharmacologic inhibition of lysine-specific demethylase 1 as a therapeutic and immune-sensitization strategy in pediatric high-grade glioma. Bailey CP; Figueroa M; Gangadharan A; Yang Y; Romero MM; Kennis BA; Yadavilli S; Henry V; Collier T; Monje M; Lee DA; Wang L; Nazarian J; Gopalakrishnan V; Zaky W; Becher OJ; Chandra J Neuro Oncol; 2020 Sep; 22(9):1302-1314. PubMed ID: 32166329 [TBL] [Abstract][Full Text] [Related]
25. Pediatric Diffuse Midline Glioma H3K27-Altered: From Developmental Origins to Therapeutic Challenges. Mandorino M; Maitra A; Armenise D; Baldelli OM; Miciaccia M; Ferorelli S; Perrone MG; Scilimati A Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791893 [TBL] [Abstract][Full Text] [Related]
26. Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location. Karremann M; Gielen GH; Hoffmann M; Wiese M; Colditz N; Warmuth-Metz M; Bison B; Claviez A; van Vuurden DG; von Bueren AO; Gessi M; Kühnle I; Hans VH; Benesch M; Sturm D; Kortmann RD; Waha A; Pietsch T; Kramm CM Neuro Oncol; 2018 Jan; 20(1):123-131. PubMed ID: 29016894 [TBL] [Abstract][Full Text] [Related]
27. Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adults. Schulte JD; Buerki RA; Lapointe S; Molinaro AM; Zhang Y; Villanueva-Meyer JE; Perry A; Phillips JJ; Tihan T; Bollen AW; Pekmezci M; Butowski N; Oberheim Bush NA; Taylor JW; Chang SM; Theodosopoulos P; Aghi MK; Hervey-Jumper SL; Berger MS; Solomon DA; Clarke JL Neurooncol Adv; 2020; 2(1):vdaa142. PubMed ID: 33354667 [TBL] [Abstract][Full Text] [Related]
28. Diffuse midline glioma with H3 K27M-mutation in an 83-year-old woman. Low JT; Wang SH; B Peters K CNS Oncol; 2021 Jun; 10(2):CNS71. PubMed ID: 33908265 [TBL] [Abstract][Full Text] [Related]
29. Potent anti-tumor efficacy of palbociclib in treatment-naïve H3.3K27M-mutant diffuse intrinsic pontine glioma. Sun Y; Sun Y; Yan K; Li Z; Xu C; Geng Y; Pan C; Chen X; Zhang L; Xi Q EBioMedicine; 2019 May; 43():171-179. PubMed ID: 31060906 [TBL] [Abstract][Full Text] [Related]
30. A kinome-wide shRNA screen uncovers vaccinia-related kinase 3 (VRK3) as an essential gene for diffuse intrinsic pontine glioma survival. Silva-Evangelista C; Barret E; Ménez V; Merlevede J; Kergrohen T; Saccasyn A; Oberlin E; Puget S; Beccaria K; Grill J; Castel D; Debily MA Oncogene; 2019 Sep; 38(38):6479-6490. PubMed ID: 31324890 [TBL] [Abstract][Full Text] [Related]
35. Advances and Clinical Trials Update in the Treatment of Diffuse Intrinsic Pontine Gliomas. Dalle Ore C; Coleman C; Gupta N; Mueller S Pediatr Neurosurg; 2023; 58(5):259-266. PubMed ID: 36642062 [TBL] [Abstract][Full Text] [Related]
36. Antisense oligonucleotide therapy for H3.3K27M diffuse midline glioma. Zhang Q; Yang L; Liu YH; Wilkinson JE; Krainer AR Sci Transl Med; 2023 Apr; 15(691):eadd8280. PubMed ID: 37043556 [TBL] [Abstract][Full Text] [Related]
37. Diffusion Characteristics of Pediatric Diffuse Midline Gliomas with Histone H3-K27M Mutation Using Apparent Diffusion Coefficient Histogram Analysis. Aboian MS; Tong E; Solomon DA; Kline C; Gautam A; Vardapetyan A; Tamrazi B; Li Y; Jordan CD; Felton E; Weinberg B; Braunstein S; Mueller S; Cha S AJNR Am J Neuroradiol; 2019 Nov; 40(11):1804-1810. PubMed ID: 31694820 [TBL] [Abstract][Full Text] [Related]
38. [Diffuse midline glioma]. Saito R No Shinkei Geka; 2022 Jan; 50(1):29-38. PubMed ID: 35169084 [TBL] [Abstract][Full Text] [Related]
39. Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma. Sewing ACP; Lagerweij T; van Vuurden DG; Meel MH; Veringa SJE; Carcaboso AM; Gaillard PJ; Peter Vandertop W; Wesseling P; Noske D; Kaspers GJL; Hulleman E J Neurosurg Pediatr; 2017 May; 19(5):518-530. PubMed ID: 28291423 [TBL] [Abstract][Full Text] [Related]
40. Current perspectives on diffuse midline glioma and a different role for the immune microenvironment compared to glioblastoma. Pachocki CJ; Hol EM J Neuroinflammation; 2022 Nov; 19(1):276. PubMed ID: 36403059 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]